二、 审议通过《2024 年公司财务决算报告》 监事会认为公司《2024 年度财务决算报告》客观、真实地反应了公司 2024 年度的财务状况和经营成果。 证券代码：300147 证券简称：ST 香雪 公告编号：2025-017 广州市香雪制药股份有限公司 第九届监事会第二十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）第九届监事会第二十次 会议于 2025 年 4 月 28 日在公司本部会议室以现场方式召开，会议通知已于 2025 年 4 月 18 日以邮件等方式送达了全体监事，会议应到监事三名，实到监事三名， 无委托出席的情况，会议由监事会主席黄伟华女士主持。本次会议的召开、议事 方式和表决程序符合《中华人民共和国公司法》和《公司章程》对召开监事会的 规定，与会监事认真审议会议议案，经表决方式通过并作出如下决议： 一、 审议通过《2024 年度监事会工作报告》 监事会审议并通过了《2024 年度监事会工作报告》，详见巨潮资讯网披露 的《2024 年度监事会工作报告》。 表决结果：同意 3 票、反 ...

证券代码：300147 证券简称：ST 香雪 公告编号：2025-016 广州市香雪制药股份有限公司 第九届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）第九届董事会第二十七 次会议于 2025 年 4 月 28 日在公司本部会议室以现场结合通讯方式召开，会议通 知已于 2025 年 4 月 18 日以邮件等方式送达了全体董事。会议应参加董事六名， 实际参加董事六名，无委托出席的情况，会议由董事长王永辉先生主持，公司监 事和高级管理人员等相关人员列席了本次会议。本次会议的召开符合《中华人民 共和国公司法》和《公司章程》的规定，经表决方式通过并作出如下决议： 二、审议通过《2024 年度总经理工作报告》 公司董事会听取了王永辉先生《2024 年度总经理工作报告》，认为 2024 年 度公司经营层有效地执行了董事会和股东会的各项决议，该报告客观、真实地反 映了公司经营管理层 2024 年度所做的主要工作。 表决结果：同意 6 票、反对 0 票、弃权 0 票。 三、审议通过《2024 年公 ...

证券代码：300147 证券简称：ST 香雪 公告编号：2025-020 广州市香雪制药股份有限公司 关于 2024 年度不进行利润分配的专项说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）第九届董事会第二十七 次会议、第九届监事会第二十次会议审议通过了《关于公司 2024 年度不进行利 润分配的议案》，该议案尚需股东大会审议通过。相关事项如下： 一、2024 年度利润分配方案 二、2024 年度不派发现金红利的情况 （一）公司 2024 年度不派发现金红利不触及其他风险警示 经北京德皓国际会计师事务所(特殊普通合伙)审计，公司 2024 年合并报表 归属于母公司所有者的净利润为-858,559,973.29 元，母公司净利润为- 545,371,600.98 元，合并报表未分配利润为-1,836,258,362.97 元，母公司未分 配利润为-625,124,201.36 元。拟定公司 2024 年度利润分配预案为：2024 年度 不派发现金红利，不送红股，不以资本公积金转增股本。 | 母公司报表本年度末累 ...

广州市香雪制药股份有限公司 关于营业收入扣除事项的 专项核查意见 德皓核字[2025]00000948 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特殊普通合伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 广州市香雪制药股份有限公司 关于营业收入扣除事项的 专项核查意见 （2024 年 1 月 1 日至 2024 年 12 月 31 日止） | | | 一、 关于营业收入扣除事项的专项核查意见 1-2 二、 营业收入扣除情况明细表 1-2 管理层负责按照监管机构上市规则及相关要求的规定编制明细表 以满足监管要求，并负责设计、执行和维护必要的内部控制，以使明 细表不存在由于舞弊或错误导致的重大错报。 二、注册会计师的责任 我们的责任是在执行审计工作的基础上对明细表发表专项核查意 关于营业收入扣除事项的 专项核查意见 德皓核字[2025] 00000948号 广州市香雪制药股份有限公司： 我们接受委托，对广州市香雪制药股份有限公司（以下简称香雪 制药）2024 年度财 ...

独立董事 2024 年度述职报告 （陶剑虹） 各位股东： 本人作为广州市香雪制药股份有限公司（以下简称"公司"）第九届董事会 的独立董事，2024 年严格按照《公司法》《上市公司独立董事管理办法》《独立 董事工作制度》《广州市香雪制药股份有限公司章程》等法律法规、规范性文件 的规定，诚信和勤勉地履行职责，积极出席相关会议，认真审议董事会各项议 案，对公司重大事项发表了独立意见，充分发挥了独立董事及各专业委员会的 作用，切实维护公司和股东特别是中小股东的合法权益。现将本人 2024 年度履 行职责情况报告如下： 广州市香雪制药股份有限公司 一、本人基本情况 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独 立性要求，不存在影响独立性的情况。履历如下： 陶剑虹，女，1958 年生，中国国籍，无境外永久居留权，博士。曾任中国 医药公司广州医药采购供应站副主任，国家药品监督管理局南方医药经济研究 所副所长，国家食品药品监督管理局南方医药经济研究所副所长，国家食品药 品监督管理总局南方医药经济研究所副所长。现任中国医药商业协会副会长， 广西柳药集团股份有限公司，科兴生物制药股份有限公司独立董事、公司独立 ...

经核查独立董事周庆权先生、吴杰先生、陶剑虹女士的任职经历以及签署的 相关自查文件，公司董事会认为上述人员未在公司担任除独立董事以外的任何职 务，也未在公司主要股东担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在其他影响独立董事独立性 的情况。公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等相关法律法规及制度中对独立董事独立性的相关要求。 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等要求，广州市香雪制药股份有限公司（以下简称"公司"）董事会就公司在任 独立董事周庆权先生、吴杰先生、陶剑虹女士的独立性情况进行评估并出具如下 专项意见： 2025 年 4 月 28 日 广州市香雪制药股份有限公司 董事会对独立董事独立性情况的专项意见 广州市香雪制药股份有限公司董事会 ...

广州市香雪制药股份有限公司 独立董事 2024 年度述职报告 各位股东： 本人作为广州市香雪制药股份有限公司（以下简称"公司"）第九届董事会 的独立董事，2024 年严格按照《公司法》《上市公司独立董事管理办法》《独立 董事工作制度》《广州市香雪制药股份有限公司章程》等法律法规、规范性文件 的规定，诚信和勤勉地履行职责，积极出席相关会议，认真审议董事会各项议 案，对公司重大事项发表了独立意见，充分发挥了独立董事及各专业委员会的 作用，切实维护公司和股东特别是中小股东的合法权益。现将本人 2024 年度履 行职责情况报告如下： 一、本人基本情况 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独 立性要求，不存在影响独立性的情况。履历如下： 吴杰，男，1970 年生，中国国籍，无境外永久居留权，本科，注册会计师。 曾任深圳特辰科技股份有限公司独立董事。现任中审众环会计师事务所（特殊 普通合伙）高级合伙人、公司独立董事。 二、2024 年度履职情况 （一）出席董事会和股东会 2024 年度，本人出席了所有应出席的董事会会议，列席了股东会，没有缺 席且未委托其他独立董事代为出席应出席会议并行使表决权的 ...

广州市香雪制药股份有限公司 独立董事 2024 年度述职报告 （周庆权） 各位股东： 本人作为广州市香雪制药股份有限公司（以下简称"公司"）第九届董事会 的独立董事，2024 年严格按照《公司法》《上市公司独立董事管理办法》《独立 董事工作制度》《广州市香雪制药股份有限公司章程》等法律法规、规范性文件 的规定，诚信和勤勉地履行职责，积极出席相关会议，认真审议董事会各项议 案，对公司重大事项发表了独立意见，充分发挥了独立董事及各专业委员会的 作用，切实维护公司和股东特别是中小股东的合法权益。现将本人 2024 年度履 行职责情况报告如下： 一、本人基本情况 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独 立性要求，不存在影响独立性的情况。履历如下： 周庆权，男，1956 年生，中国国籍，本科学历，无境外永久居留权。曾任 广州市黄埔区中医院外科主治医师、广州市黄埔区人民医院外科主治医师、副 院长、中山大学附属第一医院东院副院长、中山大学附属第一医院后勤处长。 现任公司独立董事。 二、2024 年度履职情况 （一）出席董事会和股东会 2024 年度，本人出席了所有应出席的董事会会议，列席了股东会， ...

Financial Performance - The company's operating revenue for 2024 was ¥1,858,662,132.42, a decrease of 19.16% compared to ¥2,299,287,682.53 in 2023[20] - The net profit attributable to shareholders for 2024 was a loss of ¥858,559,973.29, representing a decline of 120.73% from a loss of ¥388,963,842.58 in 2023[20] - The cash flow from operating activities for 2024 was ¥18,174,822.85, down 93.10% from ¥263,441,902.31 in 2023[20] - The total assets at the end of 2024 were ¥7,498,398,859.64, a decrease of 9.45% from ¥8,280,629,979.39 at the end of 2023[20] - The net assets attributable to shareholders decreased by 45.19% to ¥1,054,899,213.92 at the end of 2024 from ¥1,924,701,823.57 at the end of 2023[20] - The basic and diluted earnings per share for 2024 were both -¥1.3, a decline of 120.34% from -¥0.59 in 2023[20] - The company reported a significant drop in inventory levels, with pharmaceutical manufacturing inventory down 45.23% to 2,470,070 boxes[67] - The total profit amounted to -84,207.06 million yuan, reflecting a year-on-year decline of 116.5%[55] Market and Industry Outlook - The pharmaceutical industry is expected to have a broad development prospect due to factors such as aging population and increased health awareness[4] - The pharmaceutical industry in China is projected to maintain steady growth, with a market size reaching approximately $1 trillion, driven by factors such as aging population and policy support[30] - The overall outlook for the pharmaceutical industry remains positive, with ongoing support from government policies aimed at high-quality development and innovation[29] - New policies in 2024 aim to enhance drug safety and accessibility, presenting both opportunities and challenges for pharmaceutical companies[31] - The expansion of centralized procurement in 2024 is expected to optimize cost structures for pharmaceutical companies, requiring improvements in operational capabilities[33] Challenges and Risks - The company faces challenges including intensified market competition, inventory pressure, and liquidity crisis affecting its traditional Chinese medicine business[3] - The company is facing increased pressure on profit margins due to rising costs in the traditional Chinese medicine sector and the need for enhanced R&D capabilities[34] - The company faces risks from industry policy changes, raw material price fluctuations, and intensified market competition, which could adversely affect its operations[108][110][111] - New drug development is subject to significant uncertainty, with potential impacts on profitability if products fail to meet market needs or regulatory approvals[112] Research and Development - The company focuses on traditional Chinese medicine manufacturing, with a complete industry chain from cultivation to production and distribution, ensuring high-quality and efficient drug development[39] - The company is actively pursuing TCR-T cell immunotherapy technology development, collaborating with renowned research institutions to expedite product commercialization[113] - The company has received clinical trial approval for its T-cell immunotherapy products, which are currently in Phase II trials for specific cancer treatments[40] - The research and development strategy includes various collaborative models to strengthen technological reserves and adapt to market needs[43] Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation and protection of shareholder rights[124] - The company has established a fair, transparent, and effective performance evaluation and incentive mechanism for its senior management, directly linking their performance to compensation[131] - The company has a well-structured governance system, including a shareholders' meeting, board of directors, and supervisory board, operating independently from controlling shareholders[137] - The company has implemented strategies to enhance corporate governance and operational efficiency, benefiting all shareholders, especially minority shareholders[165] Environmental Responsibility - The company adheres to environmental protection standards, including the "Water Pollutant Discharge Standards for Traditional Chinese Medicine Pharmaceutical Industry" and other relevant regulations[183] - The company has invested approximately 837,600 RMB in environmental protection technology upgrades and paid an environmental protection tax of 8,800 RMB in 2024[188] - The company emphasizes environmental safety by strictly adhering to national environmental protection and emission standards, promoting energy-saving measures, and enhancing resource utilization efficiency[192] Employee Management - The total number of employees at the end of the reporting period is 2,769, with 747 in the parent company and 2,022 in major subsidiaries[170] - The company has a total of 1,032 production personnel, 587 sales personnel, and 432 technical personnel among its employees[170] - The company has established a scientific assessment system for employee compensation, linking sales personnel's pay to individual sales performance[171] - The company has implemented annual training plans focusing on corporate culture, industry policies, and professional skills to enhance employee capabilities[172] Strategic Initiatives - The company aims to enhance its core business by divesting non-core assets and focusing on efficient resource allocation to achieve sustainable growth[106] - By 2025, the company plans to improve operational efficiency and market share in the cold and cough product segments, leveraging digital transformation to optimize procurement and supply chain management[106] - The company is considering strategic acquisitions to enhance its supply chain capabilities, with a budget of 500 million yuan allocated for potential deals[150] Financial Management - The company has implemented a credit management policy to shorten accounts receivable turnover days and enhance cash flow efficiency[116] - The company has applied for financial support from local government and regulatory bodies to facilitate debt restructuring and improve liquidity[118] - The company reported a net loss from investment income of ¥6,000,458.69, reflecting losses from subsidiary disposals[84] Social Responsibility - The company maintains a commitment to social responsibility by actively participating in public welfare activities and supporting vulnerable groups in society[193] - The company donated products worth a total of 4.4004 million yuan to various groups, including frontline rescue workers and sanitation workers, through charitable foundations in 2024[192]

Financial Performance - Revenue for Q1 2025 was ¥421,004,187.88, a decrease of 25.99% compared to ¥568,856,745.84 in the same period last year[4] - Net profit attributable to shareholders was -¥87,732,945.81, representing a decline of 146.03% from -¥35,659,979.04 year-over-year[4] - The net cash flow from operating activities was -¥82,460,305.69, a significant drop of 419.44% compared to ¥25,813,931.15 in the previous year[4] - The basic and diluted earnings per share were both -¥0.13, a decline of 160.00% from -¥0.05 in the same period last year[4] - The weighted average return on equity was -8.68%, down 6.81% from -1.87% year-over-year[4] - Total operating revenue for the current period is ¥421,004,187.88, a decrease of 26.0% from ¥568,856,745.84 in the previous period[19] - The net profit for the current period is a loss of ¥80,072,625.44, compared to a loss of ¥28,629,807.17 in the previous period, representing an increase in loss of 179.5%[20] - The total comprehensive income for the current period is a loss of ¥80,115,222.89, compared to a loss of ¥28,625,879.70 in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,443,659,743.86, a decrease of 0.73% from ¥7,498,398,859.64 at the end of the previous year[4] - The company's cash and cash equivalents decreased from ¥131,741,496.06 to ¥57,521,160.42, a decline of approximately 56.4%[16] - Accounts receivable increased from ¥810,129,690.20 to ¥908,036,996.48, representing a growth of about 12.1%[16] - Inventory decreased from ¥340,919,525.62 to ¥311,394,935.92, a reduction of approximately 8.7%[16] - Total current liabilities increased from ¥5,382,016,741.51 to ¥5,777,245,299.89, an increase of about 7.3%[17] - The company's total assets decreased from ¥7,498,398,859.64 to ¥7,443,659,743.86, a decline of approximately 0.7%[17] - The total equity attributable to shareholders decreased from ¥1,054,899,213.92 to ¥967,123,670.66, a decrease of about 8.3%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 50,635[10] - The largest shareholder, Guangzhou Kunlun Investment Co., Ltd., held 22.59% of the shares, totaling 149,409,921 shares[10] Government and Regulatory Matters - The company reported a government subsidy of ¥1,202,742.95 during the period[5] - The company has not yet received a formal administrative penalty decision from the regulatory authority regarding the previous non-operating fund occupation[12] Operational Changes - The company has completed the repayment of non-operating funds occupied by the controlling shareholder, totaling ¥3,679,200.00, through a debt offset arrangement[12] - The company is currently undergoing a pre-restructuring process with appointed temporary managers to oversee the proceedings[14] - The company reported a significant increase in accounts receivable financing from ¥7,747,175.19 to ¥1,089,738.65, indicating a shift in financing strategy[16] Expenses - Total operating costs for the current period are ¥484,017,651.17, down 18.1% from ¥591,588,915.65 in the previous period[19] - Research and development expenses for the current period are ¥15,977,095.47, a decrease of 7.8% from ¥17,327,643.17 in the previous period[19] - The company incurred a credit impairment loss of ¥1,241,310.64, compared to a loss of ¥568,029.24 in the previous period[20] Audit Status - The company has not yet audited the first quarter report for the current year[25]